Factor VIII biosimilar - Dong-A ST

Drug Profile

Factor VIII biosimilar - Dong-A ST

Alternative Names: DA-3808

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Haemophilia A

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in South Korea (IV, Injection)
  • 01 Jan 2012 Dong-A Pharmaceutical's factor VIII biosimilar is available for licensing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top